Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Work In Process (2023 - 2025)

Verrica Pharmaceuticals (VRCA) has 3 years of Work In Process data on record, last reported at $523000.0 in Q2 2025.

  • For Q2 2025, Work In Process fell 23.43% year-over-year to $523000.0; the TTM value through Jun 2025 reached $523000.0, down 23.43%, while the annual FY2024 figure was $664000.0, 36.34% up from the prior year.
  • Work In Process reached $523000.0 in Q2 2025 per VRCA's latest filing, up from $179000.0 in the prior quarter.
  • Across five years, Work In Process topped out at $750000.0 in Q3 2024 and bottomed at $179000.0 in Q1 2025.
  • Average Work In Process over 3 years is $564857.1, with a median of $664000.0 recorded in 2024.
  • Peak YoY movement for Work In Process: soared 36.34% in 2024, then plummeted 73.2% in 2025.
  • A 3-year view of Work In Process shows it stood at $487000.0 in 2023, then skyrocketed by 36.34% to $664000.0 in 2024, then dropped by 21.23% to $523000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Work In Process were $523000.0 in Q2 2025, $179000.0 in Q1 2025, and $664000.0 in Q4 2024.